Search clinical trials for: lanreotide ATG 120mg

Total 3902 results

The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
BeBetter Med Inc

Completed

Study of Orally Administered BEBT-503 in Healthy Subjects

Healthy Subjects

Australia
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Guangdong Raynovent Biotech Co., Ltd

Completed

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP0678, and the Effect of Food on ZSP0678 Pharmacokinetics

Nonalcoholic Steatohepatitis

China
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (PAOLA)

Acromegaly

United States, Italy, Belgium, Saudi Arabia, Spain, France, Germany, Canada, United Kingdom, Colombia, Brazil, Israel, Turkey, Romania, Norway, Poland, Russian Federation, Argentina
Linda Van Eldik
National Institute on Aging (NIA); Duke Clinical Research Institute

Completed

MW151-101: First-in-human Study of MW151

Drug Toxicity

United States
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Hoffmann-La Roche

Completed

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

Psoriasis

United States
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
EMS

Withdrawn

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

Hypertension | Dyslipidemia
EnnovaBio Australia Pharmaceuticals Pty Ltd

Completed

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

Healthy

Australia
Impact Therapeutics, Inc.

Not yet recruiting

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition

Solid Tumor
Impact Therapeutics, Inc.

Not yet recruiting

An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition

Solid Tumor
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
IlDong Pharmaceutical Co Ltd

Completed

Pharmacokinetic Study of Belviq in Adult Korean Volunteers

Healthy

Korea, Republic of
South China Center For Innovative Pharmaceuticals
Xiangya Hospital of Central South University

Completed

Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration (AD16)

Alzheimer's Disease

China
University Hospital, Ghent

Completed

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

Malignant Intestinal Obstruction

Belgium
Genfit
Naturalpha; SGS Aster S.A.S.

Completed

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Cardiovascular Diseases | Metabolic Diseases | Diabetes Mellitus, Type 2 | Type 2 Diabetes | Dyslipidemia | Obese

France
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Stealth BioTherapeutics Inc.

Completed

A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)

Healthy

United States
West China Hospital

Recruiting

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Esophageal Squamous Cell Carcinoma

China
West China Hospital

Recruiting

Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Ipsen

Completed

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Carcinoma | Peritoneal Neoplasms | Intestinal Obstruction

France, Netherlands, Belgium
Radboud University Medical Center
Ipsen

Unknown

Open-Label Extension of LOCKCYST Trial (LOCKCYST-ext)

Liver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal Dominant

Netherlands, Belgium
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
Tranzyme, Inc.

Completed

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Gastroparesis

United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden
Ipsen

Completed

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO)

Intestinal Obstruction

Belgium
TiumBio Co., Ltd.

Recruiting

TUC3PII-01_TU2670 Phase IIa Clinical Study

Endometriosis

Czechia, Italy, Russian Federation, Poland, Ukraine
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Recruiting

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Neuroendocrine Tumors

Korea, Republic of
Federation Francophone de Cancerologie Digestive

Terminated

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

France, Belgium, Germany, United Kingdom
Kafrelsheikh University

Completed

Ridge Augmentation With Simultaneous Implant Placement Using Bone Blocks With Autogenous Tooth Graft

Implant | Ridge Augmentation | Autogenous Tooth Graft

Egypt
Lee's Pharmaceutical Limited

Completed

A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers

Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin

Hong Kong
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
Ipsen

Completed

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (CALM-NET)

NeuroEndocrine Tumours

United Kingdom
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)

Acromegaly

France, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Digestive Fistulae

France, Russian Federation
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (MEDARD)

Diarrhea

Belgium
Huahui Health

Recruiting

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Chronic Hepatitis Delta Virus Infection

China
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital, Sun Yat-Sen University

Unknown

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

Acromegaly

China

3

Subscribe